Corvus Pharmaceuticals, Inc. (CRVS)
NASDAQ: CRVS · Real-Time Price · USD
14.73
+0.17 (1.17%)
Aug 26, 2026, 4:00 PM EDT - Market closed

Corvus Pharmaceuticals Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Income
-56.96-42.97-27.55-23.33-31.98-38.4
Net Income
-54.13-15.28-62.29-27.03-41.31-43.24
Earnings Per Share
-0.62-0.53-1.02-0.56-0.89-1.03
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
215.2356.7551.9627.1542.369.45
Total Debt
0.730.941.121.372.63.65
Net Cash (Debt)
214.555.8150.8425.7839.765.8
Net Cash Growth
192.54%9.78%97.25%-35.08%-39.67%56.87%
Net Cash Per Share
2.460.700.830.540.851.57

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-44.53-32.8-25.42-23.94-27.02-36.72
Capital Expenditures
-0.7-0.17--0.03-0.27-0.01
Free Cash Flow
-45.23-32.97-25.42-23.97-27.29-36.72
Free Cash Flow Growth
------

Valuation

Selected indicators aren't available for this stock.